Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Clinical trial NCT04588987 · UNKNOWN

Trial details

NCT number: NCT04588987
Sponsor: Sun Yat-sen University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Neoadjuvant Therapy Carilizumab Apatinib Recurrent High-Grade Glioma

Start date: 2020-10-01
Primary completion: 2023-10-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.